Home › All Companies › ARTV › Annual Report

Artiva Biotherapeutics, Inc. (ARTV) — Annual Report

AI-Powered SEC Filing Analysis

← All ARTV filings
Latest Annual Report Filed: 2026-03-10

Key Insights

  • Artiva Biotherapeutics reported significant investments in research and development, indicating a focus on advancing its pipeline of cell therapy candidates.
  • The company secured several key licensing and collaboration agreements with GC Cell, suggesting progress in developing and commercializing its product candidates.
  • Artiva's financial position appears strong, with a balance sheet that includes cash, cash equivalents, and investments, providing runway to fund ongoing operations and development activities.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Artiva Biotherapeutics, Inc.

Current Report Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.